Recent 8-K filings for BCAB
Highest-materiality recent filing
BioAtla receives Nasdaq delisting notice; trading suspension effective Feb 10
- Nasdaq Hearings Panel determined to suspend BCAB common stock at open on Feb 10, 2026 for non-compliance with $1.00 bid price and $2.5M stockholders' equity requirements.
- Company requested immediate review and stay by Listing Council; Nasdaq counsel refused, but company claims precedent exists for such stays.
-
BioAtla initiates strategic review to monetize assets; Q4 net loss $9.8M, cash $7.1M
Board launched formal process to explore sale, licensing, or other strategic options; Tungsten Advisors engaged.
-
BioAtla shareholders approve 1-for-50 reverse stock split merger; executive retention bonuses set
Stockholders approved Merger and Share Consolidation (1:50 reverse split) on March 23, 2026; 49.2M votes for, 1.47M against.
-
BioAtla initiates strategic review, cuts 70% workforce; CFO replaced; cash ~$7.1M
Workforce reduced ~70%; severance costs estimated $0.5-0.6M; committed Feb 24, 2026.
-
Nasdaq Listing Council stays BCAB delisting, calls review of Feb 6 non-compliance determination
Nasdaq determined Feb 6 to delist BCAB for non-compliance with bid price ($1) and stockholders' equity ($2.5M) requirements.
-
BioAtla receives Nasdaq delisting notice; trading suspension effective Feb 10
Nasdaq Hearings Panel determined to suspend BCAB common stock at open on Feb 10, 2026 for non-compliance with $1.00 bid price and $2.5M stockholders' equity requirements.
-
BioAtla adopts 1-for-50 reverse stock split via merger after Nasdaq policy reversal; delisting risk
Issued one share of super-voting Series A Preferred to pass reverse split (100M votes for), then redeemed it for $0.01.
-
BioAtla issues super-voting share to CEO; reverse stock split vote fails, adjourned to Jan 26
Issued one share of Series A Junior Preferred Stock to CEO Jay Short for $0.01, granting vote power equal to outstanding common shares on reverse split proposals.
-
BioAtla enters $40M SPV deal to advance Oz-V Phase 3; retains 65% ownership
Total $40M from Inversagen AI for 35% of SPV units; initial $5M closing by Jan 30, 2026.
-
BioAtla special meeting adjourned; reverse stock split proposal lacks sufficient votes
Proposal 1 (issuance of common stock under pre-paid advance agreements) passed: 19.8M for, 9.4M against.
-
BioAtla raises $7.5M via PPAs and $15M SEPA; Yorkville gets 243,428 commitment shares
PPAs for $7.5M face amount; net proceeds ~$7.13M at 95% of face; due in 12 months.
-
BioAtla Q3 net loss $15.8M; FDA aligns on Phase 3 Oz-V design; partnership on track by year-end
Q3 2025 net loss $15.8M vs $10.6M in 2024 (which included $11M Context collaboration revenue); cash $8.3M at Sept 30.
-
BioAtla granted Nasdaq continued listing with conditions through Feb 2026
Nasdaq Panel approved continued listing pending transfer to Capital Market by Sept 26, 2025 (filed Sept 18).
-
BioAtla Q2 net loss $18.7M; cash $18.2M; Oz-V 45% ORR in HPV+ OPSCC
Net loss of $18.7M for Q2 2025 vs $21.1M in Q2 2024; R&D expense down to $13.7M.
-
BioAtla receives Nasdaq delisting notice for failing $10M equity requirement
Stockholders' equity was $547K as of March 31, 2025, far below the $10M minimum for Nasdaq Global Market.
-
BioAtla Q1 net loss $15.3M; cash $32.4M; Mec-V shows 59% 2-year OS in mKRAS NSCLC
Net loss $15.3M vs $23.2M YoY; R&D expenses down to $12.4M from $18.9M.
-
BioAtla reports Q4 net loss $14.9M, cuts workforce 30% to extend runway to 1H 2026 clinical readouts
Net loss $14.9M in Q4 2024 vs $26.9M Q4 2023; cash $49.0M at year-end vs $111.5M.
-
BioAtla receives Nasdaq notice of non-compliance with minimum bid price rule; 180 days to cure
Received Nasdaq notice on Feb 6, 2025 for failing minimum bid price of $1.00 for 30 consecutive business days.
-
BioAtla raises $9.2M in registered direct offering to fund mid-stage TCE and ADC programs
Sold 9,679,158 shares and accompanying warrants at $0.9520/unit; gross proceeds ~$9.2M.
-
BioAtla Q3 net loss narrows to $10.6M on $11M collaboration revenue; cash runway into early 2026
Q3 net loss $10.6M vs $33.3M in Q3 2023; R&D expenses fell to $16.4M from $28.4M.
-
BioAtla licenses Nectin-4 x CD3 bispecific antibody to Context Therapeutics for up to $133.5M
BioAtla grants exclusive worldwide license to Context for two antibodies including BA3362 (CT-202), a Nectin-4 x CD3 TCE bispecific.
-
BioAtla Q2 net loss $21.1M; cash to Q3 2025; Fast Track for ozuriftamab vedotin
Net loss of $21.1M for Q2 2024 vs $35.8M in Q2 2023; R&D expenses fell to $16.2M from $31.0M.
-
Net loss $23.2M in Q1 2024 vs $27.5M in Q1 2023; cash $80.6M as of March 31, 2024.
-
BioAtla Q4 net loss $26.9M; cash $111.5M; multiple Phase 2 readouts on track for 2Q 2024
Net loss Q4 2023: $26.9M vs $27.6M Q4 2022; R&D expense $22.7M vs $21.9M.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.90 · Median 0.70 · Most common event other_material